Form 4: Incyte CFO's Stock Holdings Adjusted for Routine Tax Withholding

Incyte Corporation's EVP & Chief Financial Officer, Christiana Stamoulis, reported a routine disposition of 11,589 shares of common stock to satisfy tax withholding obligations related to vested equity, with her beneficial ownership now totaling 117,504 shares.

Summary

• Christiana Stamoulis, Executive Vice President and Chief Financial Officer of Incyte Corp (INCY), reported a change in beneficial ownership.
• On July 2, 2025, 11,589 shares of Incyte Common Stock were disposed of at a price of $68.17 per share.
• This disposition represents shares automatically withheld by Incyte to cover tax withholding obligations due upon the settlement of previously reported Restricted Stock Units (RSUs) or earned performance shares.
• Following this transaction, Christiana Stamoulis beneficially owns 117,504 shares of Incyte Common Stock.
• The total beneficial ownership includes 59,103 shares of common stock issuable from previously reported RSUs and earned performance shares that have not yet vested.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a routine, non-discretionary tax withholding event related to equity compensation, not indicative of positive or negative operational or financial performance.

Positives

• The transaction is a non-discretionary, routine event for tax withholding on vested equity, not a sale initiated by the officer.
• The EVP & CFO retains a substantial beneficial ownership of 117,504 shares, indicating continued alignment with shareholder interests.

Future Outlook

NA

Industry Context

This type of transaction, involving the withholding of shares to cover tax liabilities upon the vesting of equity awards, is a standard and common practice across all industries for executives receiving equity-based compensation. It reflects the routine administration of compensation plans rather than a discretionary trading decision.

Comparison to Industry Standards

• The practice of withholding shares for tax obligations upon equity vesting is a standard industry practice for publicly traded companies, aligning with common compensation and tax compliance procedures.
• This transaction is consistent with how equity compensation is typically handled for executives across the pharmaceutical and biotechnology sectors, including companies like Pfizer, Merck, or Bristol Myers Squibb, where executives often receive a significant portion of their compensation in equity.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine administrative transaction related to executive compensation, not a discretionary sale or a significant change in the company's capital structure.

Key Dates

Keywords

Incyte, INCY, Form 4, SEC filing, insider transaction, stock ownership, CFO, tax withholding, RSU, performance shares, equity compensation